Table 2.

Outcomes of contemporary published prospective trials of intensive chemotherapy induction regimens with or without the incorporation of venetoclax.

Trial	Design	AML type	Age, median (range)	Risk Group	Response	Survival	Early mortality
FIA versus CIA				ELN 2010		2-year
FIA (N = 76)	Phase 2	ND-AML	49 (18–66)	int-2/adverse: 58%	ORR: 83%; CR/CRp: 82%; MRD-neg: 65%	57%	60 days: 1%
CIA (N = 106)	Phase 2	ND-AML	53 (20–66)	int-2/adverse: 57%	ORR: 83%; CR/CRp: 80%; MRD-neg: 80%	51%	60 days: 4%
FLAG-IDA versus ADE				Cytogenetic risk		8-year
FLAG-IDA (N = 635)	Phase 3	ND-AML	48 (0–71)	Int: 69%, Adv: 13%	ORR: 86%, CR: 84%	44%	Induction: 7%
ADE (N = 633)	Phase 3	ND-AML	48 (0–67)	Int: 72%, Adv: 13%	ORR: 85%, CR: 81%	37%	Induction: 7%
DA versus DAC. versus DAF				SWOG criteria		3-year
DAC (N = 222)	Phase 3	ND-AML	48 (18–60)	Int: 52%, Adv: 16%	ORR: 68%, CR: 62%	45%	Induction: 11%
DAF (N = 219)	Phase 3	ND-AML	47 (17–60)	Int: 51%, Adv: 18%	ORR: 59%, CR: 55%	35%	Induction: 9%
DA (N = 211)	Phase 3	ND-AML	47 (18–60)	Int: 50%, Adv: 18%	ORR: 56%, CR: 51%	33%	Induction: 10%
CPX-351 versus “7 + 3”			Mean (SD)	NCCN criteria		5-year
CPX-351 (N = 153)	Phase 3	sAML	67.8 (4.2)	Int: 45%, Adv: 50%	CR/CRi: 48%, CR: 37%	18%	60 days: 13.7%
“7 + 3” (N = 156)	Phase 3	sAML	67.7 (4.1)	Int: 40%, Adv: 57%	CR/CRi: 36%, CR: 30	8%	60 days: 21.2%
FLAG-IDA + VEN				ELN 2017		1-year
ND-AML (N = 29)	Phase 2	ND-AML	45 (20–65)	Int: 45%, Adv: 38%	ORR: 97%, CRc:90%, MRD-neg: 96%	94%	30 days: 0%
R/R-AML (N = 16)	Phase 1b	R/R-AML	51 (20–73)	Int: 13%, Adv: 50%	ORR: 75%, CRc: 75%, MRD-neg: 58%	38%	30 days: 0%
R/R-AML (N = 23)	Phase 2	R/R-AML	47 (22–66)	Int: 13%, Adv: 61%	ORR: 70%, CRc: 61%, MRD-neg: 79%	68%	30 days: 0%
CLIA + VEN				ELN 2017		1-year
	Phase 1b/2	ND-AML	48 (37–56)	Int: 30%, Adv: 35%	ORR: 94%, CRc: 94%, MRD-neg: 71%	85%	60 days: 2%
“5 + 2”+VEN				ELN 2017		median
	Phase 1b	ND-AML	72 (63–80)	Int: 31%, Adv: 49%	ORR: 72%, CR: 41%	11.2 mo.	30 days: 6%